Farnesyl protein transferase inhibitors and other therapies targeting the Ras signal transduction pathway.
The year 2000 will be a significant date for the field of Ras-related therapies since numerous agents will have Phase II clinical efficacy data maturing to provide proof of principle for this cancer treatment strategy. These data will also provide an important milestone for the cancer research community since these molecules represent a small vanguard of oncology drug discovery projects predicated on molecular targets. We can only hope that these agents are a successful harbinger for the formidable number of targeted therapies that will be entering development pipelines in the coming years.
End
D W
DW
Department of Oncology, Janssen Research Foundation, Spring House, PA 19477, USA. DEND@PRIUS.JNJ.COM
D019883:Alkyl and Aryl Transferases / Q000037:antagonists & inhibitors* / Q000502:physiology; D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D053138:Cyclohexenes; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D000077222:Limonene; D016376:Oligonucleotides, Antisense / Q000494:pharmacology; D011499:Protein Processing, Post-Translational; D019908:Proto-Oncogene Proteins c-raf / Q000037:antagonists & inhibitors; D015398:Signal Transduction / Q000187:drug effects*; D013729:Terpenes / Q000494:pharmacology; D018631:ras Proteins / Q000502:physiology*
D000970:Antineoplastic Agents; D053138:Cyclohexenes; D004791:Enzyme Inhibitors; D016376:Oligonucleotides, Antisense; D013729:Terpenes; D000077222:Limonene; D019883:Alkyl and Aryl Transferases; C064911:p21(ras) farnesyl-protein transferase; D019908:Proto-Oncogene Proteins c-raf; D018631:ras Proteins